Related Experiment Video

Updated: Mar 28, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.9K

Predictive factors of response to mTOR inhibitors in neuroendocrine tumours

Maria Chiara Zatelli1, Giuseppe Fanciulli2, Pasqualino Malandrino2

  • 1Section of Endocrinology and Internal MedicineDepartment of Medical Sciences, University of Ferrara, Via Aldo Moro 8, 44124 Cona - Ferrara, ItalyNeuroendocrine Tumours UnitDepartment of Clinical and Experimental Medicine, University of Sassari - AOU Sassari, Sassari, ItalyEndocrinology UnitGaribaldi Nesima Medical Center, Catania, ItalyDepartment of Clinical Medicine and Surgery"Federico II" University of Naples, Naples, ItalyThyroid and Parathyroid Surgery UnitIstituto Nazionale per lo studio e la cura dei tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy ztlmch@unife.it.

Endocrine-Related Cancer
|December 16, 2015
PubMed

Insights

Identifying biomarkers for mTOR inhibitors (rapalogs) is crucial for effectively treating neuroendocrine tumors (NETs). This review explores tissue, circulating, and imaging markers to predict patient response to rapalog therapy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Neuroendocrine tumors (NETs) treatment has advanced with drugs like somatostatin analogs, tyrosine kinase inhibitors, and mTOR inhibitors (rapalogs).
  • Rapalogs are approved for advanced pancreatic NETs and show efficacy in various NET types, though treatment resistance can occur.
  • Predicting which patients will benefit from rapalogs is essential for personalized treatment and efficient healthcare resource allocation.

Purpose of the Study:

  • To review current data on predictive markers for rapalog efficacy in neuroendocrine tumors (NETs).
  • To identify potential tissue, circulating, and imaging biomarkers for tailored patient management.

Main Methods:

  • Literature review of studies investigating predictive markers for rapalog treatment in NETs.
  • Analysis of data on tissue-based, blood-based (circulating), and imaging markers.

Main Results:

  • Various markers are under investigation for their potential to predict response to rapalog therapy in NETs.
  • Identifying these markers could help select patients likely to benefit, avoiding ineffective treatments.

Conclusions:

  • Predictive markers are vital for optimizing rapalog treatment selection in NET patients.
  • Further research into tissue, circulating, and imaging markers will enhance personalized medicine approaches for NETs.
Keywords:
mTOR inhibitorsneuroendocrine tumourspredictorsresponse to treatment

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K